Clinical trials: Single Dose
Healthy
Bioequivalence Study of Two Strengths of Two Different Metformin Tablets Administered to Healthy Male and Female Subjects
Investigation of bioequivalence of BMS Glucophage® tablets and Merck Glucophage® tablets in the strengths of 1000 mg (part I) and 500 mg (part II)
- Trial name
- NCT02183571
- Testing
- Merck Glucophage® high dose, BMS Glucophage® high dose, Merck Glucophage® low dose
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Pharmacokinetic Analysis
An Open Label Pharmacokinetic Study of ASP-001 Formulations in Healthy Volunteers
This study will assess the pharmacokinetics (PKs), safety and tolerability of ASP-001 in healthy volunteers. ASP-001 is an orally disintegrating tablet (ODT) formulation of flunarizine.
- Trial name
- NCT07445464
- Testing
- Flunarizine
- Where
- Australia
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Aspartes Pharmaceuticals, Inc.
Advanced Glioblastoma, Advanced Colorectal Cancer
A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer
ONC201 is a new potential drug that kills cancer cells but not normal cells in laboratory studies. This clinical trial will be the first evaluation of ONC201 in humans and will enroll patients with advanced cancer.
- Conditions
- Advanced Glioblastoma, Advanced Colorectal Cancer, Advanced Triple-negative Breast Cancer, Advanced Non-small Cell Lung Cancer
- Trial name
- NCT02038699
- Testing
- ONC201
- Where
- United States
- Sponsor
- Jazz Pharmaceuticals
Pharmacokinetics, Drug Interactions
Pharmacokinetic Drug Interaction Between Ezetimibe and Sirolimus After Single Dose Administration in Healthy Subjects
The purpose of this study is to confirm a significant influence of ezetimibe and sirolimus on each others pharmacokinetics
- Conditions
- Pharmacokinetics, Drug Interactions, Hypercholesterolemia, Immunosuppression
- Trial name
- NCT00621101
- Testing
- 1 tablet Ezetrol(R) (ezetimibe), MSD Sharp & Dohme GmbH, Germany, 1 tablet Rapamune(R) (sirolimus), Wyeth Pharma, Germany, 1 tablet Ezetrol(R) + 1 tablet Rapamune(R)
- Where
- Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University Medicine Greifswald
Cancer
A Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies
This is an open-label, randomized, single-dose, 2-treatment, 2-period, 2-way crossover study with incomplete wash-out in subjects with solid tumors to determine the relative bioavailability of test formulation with lower dimethyl…
- Trial name
- NCT01725100
- Testing
- GSK1120212B (Standard DMSO content), GSK1120212B (Lower DMSO content)
- Where
- 4 sites in United States
- Volunteers
- 80 people
- Sponsor
- GlaxoSmithKline
Health Volunteers
The Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]OD-001 in Healthy Male Participants
This study looks at how the body handles an investigational drug called OD-001. Researchers want to learn how the medicine is absorbed, how it is broken down, and how it leaves the body.
- Trial name
- NCT07900607
- Testing
- [14C]OD-001
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Odyssey Therapeutics, Inc.
Glioblastoma, Recurrent Glioblastoma
Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma
This early phase I trial tests brain concentration level and safety of defactinib or VS-6766 for the treatment of patients with glioblastoma.
- Trial name
- NCT05798507
- Testing
- Avutometinib, Biospecimen Collection, Defactinib
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Emory University
Hepatic Impairment
A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Various Degrees of Hepatic Impairment
The primary objective of the study is to evaluate the pharmacokinetics (PK) of a single dose of olpasiran in participants with mild, moderate, or severe hepatic impairment compared to participants with normal hepatic function.
- Trial name
- NCT05481411
- Testing
- Olpasiran
- Where
- 3 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Amgen
Healthy Subjects
Mass Balance Study of ASP1941
This study investigates the pharmacokinetics, in particular the routes and extent of metabolism and excretion, of ASP1941 after a single oral dose.
- Trial name
- NCT01302132
- Testing
- ASP1941
- Where
- Netherlands
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
Healthy Participants
Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of BOS161721 in Healthy Subjects
Study BOS161721-01 is a randomized, single center, double-blind, placebo-controlled trial conducted to study the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending intravenous (IV) and subcutaneous (SC)…
- Trial name
- NCT03036865
- Testing
- BOS161721
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Boston Pharmaceuticals
Chronic Hepatitis B in Adults and Paediatric Patients
Bioequivalence Study of Two Products of Tenofovir Alafenamide 25 mg Film Tablet in Healthy, Adult, Human Subjects
To compare the bioavailability and characterize the pharmacokinetic profile of the sponsor's test product relative to that of reference product after single oral dose, fully replicate, bioequivalence study in normal, healthy…
- Trial name
- NCT06592300
- Testing
- Tenofovir Alafenamide Film coated Tablet, Vemlidy® film-coated tablets
- Where
- India
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi
Overweight or Obesity, Type 2 Diabetes
Phase 1 to Study Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NA-931 in Obese Participants and Patients With Type 2 Diabetes Mellitus
A randomized, double-blind, placebo-controlled, dose escalation, first in human study designed to assess the safety and tolerability, pharmacokinetics, and pharmacodynamics of NA-931 when administered as single and…
- Trial name
- T2DM (NCT06615700)
- Testing
- NA-931
- Where
- 2 sites in Australia
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Biomed Industries, Inc.
Allogeneic Hematopoietic Stem Cell Transplantation Recipient
High Dose Vitamin A in Preventing Gastrointestinal GVHD in Participants Undergoing Donor Stem Cell Transplant
This phase I trial studies the side effects and how well high dose vitamin A works in preventing gastrointestinal graft versus host disease (GVHD) in participants undergoing donor stem cell transplant.
- Trial name
- NCT03719092
- Testing
- Vitamin A Compound, Best Practice
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Thrombosis
Single-dose Pharmacokinetics of BMS-986177 in Participants With Hepatic Impairment Compared to Healthy Participants
A single oral dose of BMS-986177 administered to subjects of mild hepatic impairment, moderate hepatic impairment and healthy matched subjects to evaluate pharmacokinetics, safety, and tolerability in these subjects
- Trial name
- NCT02982707
- Testing
- BMS-986177
- Where
- 3 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Schizophrenia, Schizophrenic Disorders
Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.
The purpose of this open-label study is to evaluate the long-term (6-month) safety and tolerability of extended-release paliperidone, an atypical antipsychotic, given in flexible dosages to adolescents with schizophrenia.
- Conditions
- Schizophrenia, Schizophrenic Disorders, Psychotic Disorders, Dementia Praecox
- Trial name
- NCT00488319
- Testing
- Paliperidone ER
- Where
- 53 sites in United States, Belgium and 9 more
- Volunteers
- 400 people
- Sponsor
- Janssen Research & Development, LLC
Asthma, Atopic Dermatitis
A Single Ascending Dose Study in Healthy Participants and Multiple Ascending Dose Study of CNTO 7160 in Participants With Asthma and Participants With Atopic Dermatitis
The purpose of this study is to evaluate the safety and tolerability of single ascending dose of CNTO 7160 administered intravenously (IV) in healthy participants and multiple dose administered IV in participants with asthma and…
- Conditions
- Asthma, Atopic Dermatitis, Healthy
- Trial name
- NCT02345928
- Testing
- Part 1: CNTO 7160, Part 2 (Asthma): CNTO 7160, Part 2 (Atopic Dermatitis): CNTO 7160
- Where
- 7 sites in Belgium, Germany
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy
To Determine the Fasting Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets
The purpose of this study is to assess the bioequivalence of a new oxycodone formulation (40 mg) relative to the original OxyContin® (OXY) formulation (40 mg) in the fasted state.
- Trial name
- NCT01101165
- Testing
- Reformulated OXY (oxycodone HCl), Original OxyContin® (OXY) (oxycodone HCl)
- Where
- United States
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Purdue Pharma LP
Obesity
A Research Study Investigating Safety and Concentration in the Blood After One Dose Tablet of the New Medicine Monlunabant in Healthy Weight Japanese and Caucasian Men
The study is testing a new study drug in healthy normal weight Japanese and Caucasian participants after a single dose. The aim of this study is to see if the new medicine is safe and how it works in the participants body.
- Trial name
- NCT06542536
- Testing
- Monlunabant
- Where
- United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Healthy Subjects
Safety Study of BMS-986165 in Healthy Subjects and to Treat Psoriasis
The purpose of this study is to establish if BMS-986165 is safe and effective at treating autoimmune diseases. BMS-986165 which has shown some promise in preclinical studies for inhibiting autoimmune conditions.
- Trial name
- NCT02534636
- Testing
- BMS-986165, Interferon alpha-2a recombinant, Famotidine
- Where
- Australia
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Healthy Volunteers
A Study to Evaluate the Safety, Tolerability and Amount of EI-1071 in Blood in Healthy Volunteers
This was a first-in-human study to determine the safety, tolerability, and pharmacokinetics of EI1071 after single and multiple doses in healthy volunteers.
- Trial name
- NCT04238364
- Testing
- EI-1071
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Elixiron Immunotherapeutics Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.